In cell cultures analyzed in the current study, hrsACE2 inhibited the coronavirus load by a factor of 1,000-5,000. Credit: IMBA/Tibor Kulcsar
Cell-free production method scales up yield by 5,000 times
Researchers are ramping up production of a promising drug that has proven effective in obliterating SARS-CoV in cellular cultures. The team hopes that the drug might also be effective in the fight against SARS’s close genetic cousin, the novel coronavirus (COVID-19).
Led by Northwestern University and ShanghaiTech University, the team has produced the promising molecule, called valinomycin, in a cell-free system. With this approach, they increased production yields more than 5,000 times in just a few rapid design cycles, achieving higher concentrations of the molecule than achieved previously in cells.
“Because we use cell-free systems, we can optimize production faster than in cells to further increase yields,” said Northwestern’s Michael Jewett, who co-led the study. “For example, pathway optimization cycles take days rather than weeks or months, and this speed could be ever so important when dealing with a pandemic like the coronavirus COVID-19 outbreak.”
The research was published online recently in the journal Metabolic Engineering and will appear in the July 2020 print issue.
Jewett is the Walter P. Murphy Professor of Chemical and Biological Engineering in the McCormick School of Engineering and director of Northwestern’s Center for Synthetic Biology. He co-led the work with Jian Li, an assistant professor in the School of Physical Science and Technology at ShanghaiTech.
Jewett leads multiple projects that use cell-free biotechnology to accelerate COVID-19 therapeutics. His group takes the molecular machinery out of cells, and then uses that machinery to make a product, such as therapeutics, in a safe, inexpensive and rapid manner. The idea is akin to opening the hood of a car and removing the engine, which allows researchers to use the engine for different purposes, free from the constraints of the car.
5,000x
Cell-free method increases yield by 5,000-fold
A naturally occurring peptide, valinomycin has recently emerged as a potential antiviral to treat SARS. Jewett imagines using cell-free synthetic biology to find similar molecules or to modify valinomycin to make it safer and more potent.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
COVID-19 drug development
- UW’s Baker Lab researchers make AI strides in drug-like peptides
In recent years, artificial intelligence programs for drug design have steadily shown they can help explore far beyond just small-molecule drugs—by illuminating how proteins fold and interact, all | ...
- Malaria is still killing people in Kenya, but a vaccine and local drug production may help
Malaria is still a significant public health challenge in Kenya, but an important pilot of the world’s first malaria vaccine may help ...
- Big Pharma's ROI for drug R&D saw 'welcome' rebound in 2023: report
Eagle-eyed watchers of Deloitte’s annual reports on Big Pharma will have noticed a depressing trend—ever-increasing costs for developing drugs over the past decade as the return on investment sinks | ...
- European Commission approves Astellas’ drug for expanded prostate cancer Treatment
Astellas Pharma Inc. revealed that XTANDITM (enzalutamide) has received a label extension from the European Commission, marking it as the inaugural and only novel hormone therapy endorsed for ...
- Analysis finds significant variations in national COVID-19 treatment recommendations
National clinical guidelines for the treatment of COVID-19 vary significantly around the world, with under-resourced countries the most likely to diverge from gold standard (World Health Organization; ...
Go deeper with Google Headlines on:
COVID-19 drug development
[google_news title=”” keyword=”COVID-19 drug development” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Valinomycin
- Startseite Lexika Lexikon der Chemie Aktuelle Seite:
Valinomycin, cyclo-(-D-Val-Lac-Val-D-Hyv-) 3, ein ringförmiges Depsipeptid mit ionenselektiver antibiotischer Wirkung. Das nach seinem hohen Valingehalt bezeichnete V. enthält als nichtproteinogene ...
- Startseite Lexika Lexikon der Biochemie Aktuelle Seite:
Valinomycin, cyclo-(D-Val-Lac-Val-D-Hyv-) 3, ein ringförmiges 12AS-Depsipeptid mit ionenselektiver antibiotischer Wirkung aus Streptomyces fulvissimus. V. ist aktiv gegen den Tuberkuloseerreger ...
Go deeper with Google Headlines on:
Valinomycin
[google_news title=”” keyword=”valinomycin” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]